DUBLIN, March 19, 2021 /PRNewswire/ -- Cosmo Pharmaceuticals NV (SIX: COPN) invites investors, financial analysts and business/lifescience journalists for a telephone conference on 26 March 2021 with CEO Alessandro Della Chà and CFO Niall Donnelly to discuss the 2020 results and 2021 outlook of the company.

Cosmo Pharmaceuticals Logo

Date:  Friday, 26 March 2021
Time: 02:00 pm CET

Dial-in numbers:
Switzerland / Europe: +41 (0) 58 310 50 00
United Kingdom: +44 (0) 207 107 06 13
United States: +1 (1) 631 570 56 13

The presentation and press release as well as the Annual Report 2020 will be available for download as of 07:00 am CET on 26 March 2021 on www.cosmopharma.com

About Cosmo Pharmaceuticals

Cosmo is a specialty pharmaceutical company focused on developing and commercialising products to treat selected gastrointestinal disorders and improve endoscopy quality measures through aiding the detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has recently entered into a partnership with Medtronic for the global distribution of GI Genius its artificial intelligence device for use in coloscopies and GI procedures. Cosmo has licensed Aemcolo® to Red Hill Biopharma Ltd. for the US and has licensed Relafalk® to Dr. Falk Gmbh for the EU and other countries. For additional information on Cosmo and its products please visit the Company's website: www.cosmopharma.com

Calendar
2020 Full Year Results and 2021 Outlook - March 26, 2021
Annual General Meeting, Amsterdam - May 28, 2021

 

 

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/invitation-to-cosmos-2020-results--2021-outlook-presentation-conference-call-on-26-march-2021-301250513.html

SOURCE Cosmo Pharmaceuticals N.V.

Copyright 2021 PR Newswire

Cosmo Pharmaceuticals Nv (LSE:0RGI)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024 Haga Click aquí para más Gráficas Cosmo Pharmaceuticals Nv.
Cosmo Pharmaceuticals Nv (LSE:0RGI)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024 Haga Click aquí para más Gráficas Cosmo Pharmaceuticals Nv.